S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
S&P 500   3,453.49 (+0.52%)
DOW   28,363.66 (+0.54%)
QQQ   284.18 (+0.00%)
AAPL   115.75 (-0.96%)
MSFT   214.89 (+0.04%)
FB   278.12 (-0.22%)
GOOGL   1,606.66 (+1.30%)
AMZN   3,176.40 (-0.27%)
TSLA   425.79 (+0.75%)
NVDA   534.44 (-1.21%)
BABA   306.28 (-0.55%)
CGC   20.30 (+4.16%)
GE   7.72 (+5.46%)
MU   54.38 (+2.01%)
AMD   79.42 (+0.28%)
T   28.28 (+5.84%)
F   8.21 (+4.59%)
ACB   4.85 (+0.00%)
GILD   60.67 (+0.76%)
NFLX   485.23 (-0.78%)
BA   169.07 (+3.18%)
NIO   27.38 (-1.72%)
BAC   24.87 (+3.41%)
Log in
NASDAQ:RVNC

Revance Therapeutics Stock Forecast, Price & News

$23.90
+0.23 (+0.97 %)
(As of 10/22/2020 04:30 PM ET)
Add
Compare
Today's Range
$23.35
Now: $23.90▼
$24.29
50-Day Range
$24.73
MA: $27.44▼
$34.30
52-Week Range
$11.78
Now: $23.90▼
$34.62
Volume533,137 shs
Average Volume704,367 shs
Market Capitalization$1.58 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.77
Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine. It is also developing DAXI for forehead lines and lateral canthal lines; DaxibotulinumtoxinA Topical for therapeutic and aesthetic applications; and OnabotulinumtoxinA, a biosimilar to BOTOX. Revance Therapeutics, Inc. has a collaboration agreement with Mylan Ireland Limited for the development, manufacture, and commercialization of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Read More
Revance Therapeutics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 3.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.53 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RVNC
Previous Symbol
CUSIPN/A
CIK1479290
Webwww.revance.com
Phone510-742-3400
Employees170

Debt

Debt-to-Equity Ratio0.68
Current Ratio10.48
Quick Ratio10.46

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$410,000.00
Price / Sales3,843.12
Cash FlowN/A
Price / Cash FlowN/A
Book Value$5.00 per share
Price / Book4.78

Profitability

EPS (Most Recent Fiscal Year)($3.67)
Net Income$-159,430,000.00
Net Margins-42,532.11%
Return on Equity-88.96%
Return on Assets-47.15%

Miscellaneous

Outstanding Shares65,928,000
Market Cap$1.58 billion
Next Earnings Date11/2/2020 (Estimated)
OptionableOptionable
$23.90
+0.23 (+0.97 %)
(As of 10/22/2020 04:30 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RVNC News and Ratings via Email

Sign-up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Revance Therapeutics (NASDAQ:RVNC) Frequently Asked Questions

How has Revance Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Revance Therapeutics' stock was trading at $17.97 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RVNC stock has increased by 33.0% and is now trading at $23.90.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Revance Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Revance Therapeutics.

When is Revance Therapeutics' next earnings date?

Revance Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, November 2nd 2020.
View our earnings forecast for Revance Therapeutics.

How were Revance Therapeutics' earnings last quarter?

Revance Therapeutics Inc (NASDAQ:RVNC) released its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.12) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.96) by $0.16. The biopharmaceutical company had revenue of $0.30 million for the quarter, compared to analyst estimates of $1.05 million. Revance Therapeutics had a negative return on equity of 88.96% and a negative net margin of 42,532.11%.
View Revance Therapeutics' earnings history.

What price target have analysts set for RVNC?

9 equities research analysts have issued 12 month target prices for Revance Therapeutics' shares. Their forecasts range from $15.00 to $42.00. On average, they expect Revance Therapeutics' stock price to reach $31.00 in the next year. This suggests a possible upside of 29.7% from the stock's current price.
View analysts' price targets for Revance Therapeutics.

Are investors shorting Revance Therapeutics?

Revance Therapeutics saw a drop in short interest in the month of September. As of September 15th, there was short interest totaling 4,430,000 shares, a drop of 18.6% from the August 31st total of 5,440,000 shares. Based on an average trading volume of 589,800 shares, the days-to-cover ratio is currently 7.5 days.
View Revance Therapeutics' Short Interest.

Who are some of Revance Therapeutics' key competitors?

Some companies that are related to Revance Therapeutics include Perrigo (PRGO), Bausch Health Companies (BHC), Arrowhead Pharmaceuticals (ARWR), Blueprint Medicines (BPMC), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Emergent Biosolutions (EBS), BridgeBio Pharma (BBIO), Biohaven Pharmaceutical (BHVN), Amicus Therapeutics (FOLD), Arena Pharmaceuticals (ARNA), Turning Point Therapeutics (TPTX), Allakos (ALLK), Evotec (EVTCY) and FibroGen (FGEN).
View all competitors.

What other stocks do shareholders of Revance Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revance Therapeutics investors own include Evolus (EOLS), Exelixis (EXEL), SCYNEXIS (SCYX), AbbVie (ABBV), Myovant Sciences (MYOV), Nektar Therapeutics (NKTR), Sorrento Therapeutics (SRNE), Bausch Health Companies (BHC), Catalyst Pharmaceuticals (CPRX) and Sangamo Therapeutics (SGMO).

Who are Revance Therapeutics' key executives?

Revance Therapeutics' management team includes the following people:
  • Mr. L. Daniel Browne, Co-Founder, Pres, CEO & Director (Age 57)
  • Mr. Tobin C. Schilke, CFO & Principal Accounting Officer (Age 44)
  • Dr. Abhay Joshi, Chief Operating Officer (Age 56)
  • Ms. Caryn Gordon McDowell, Sr. VP, Gen. Counsel & Corp. Sec. (Age 49)
  • Ms. Jeanie D. Herbert, Sr. Director of Investor Relations & Corp. Communications

What is Revance Therapeutics' stock symbol?

Revance Therapeutics trades on the NASDAQ under the ticker symbol "RVNC."

Who are Revance Therapeutics' major shareholders?

Revance Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include First Midwest Bank Trust Division (0.05%) and Edge Wealth Management LLC (0.01%). Company insiders that own Revance Therapeutics stock include Aubrey Rankin, Cyril Allouche and L Daniel Browne.
View institutional ownership trends for Revance Therapeutics.

Which institutional investors are selling Revance Therapeutics stock?

RVNC stock was sold by a variety of institutional investors in the last quarter, including Edge Wealth Management LLC.
View insider buying and selling activity for Revance Therapeutics.

Which institutional investors are buying Revance Therapeutics stock?

RVNC stock was purchased by a variety of institutional investors in the last quarter, including First Midwest Bank Trust Division.
View insider buying and selling activity for Revance Therapeutics.

How do I buy shares of Revance Therapeutics?

Shares of RVNC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Revance Therapeutics' stock price today?

One share of RVNC stock can currently be purchased for approximately $23.90.

How big of a company is Revance Therapeutics?

Revance Therapeutics has a market capitalization of $1.58 billion and generates $410,000.00 in revenue each year. The biopharmaceutical company earns $-159,430,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Revance Therapeutics employs 170 workers across the globe.

What is Revance Therapeutics' official website?

The official website for Revance Therapeutics is www.revance.com.

How can I contact Revance Therapeutics?

Revance Therapeutics' mailing address is 7555 GATEWAY BLVD., NEWARK CA, 94560. The biopharmaceutical company can be reached via phone at 510-742-3400 or via email at [email protected]

This page was last updated on 10/22/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.